Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Solution to Ecological Protection: Saving Nature for People in the future - 2Manual for Savvy Home Lighting Framework: Lights up Your Space
- 3The Difficulties of Getting a Green Card in the US
- 4How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- 5Trump signs a law returning whole milk to school lunches
- Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- Astounding Treehouses All over the Planet
- 8 Espresso Bean Starting points All over the Planet
- Fake new headlights rule steer Australian drivers astray
- Best Amusement Park in Asia: Which One Is a Must-Visit
- 2025 Yachting Editors' Choice Awards: Yachts
- Does physics say that free will doesn't exist?
- Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
